Melanoma Clinical Trial
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
In the opinion of the Investigator would benefit from continued treatment.
Patient has been previously permanently discontinued from study treatment in the parent protocol.
Patient's indication is commercially available and reimbursed in the local country.
Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 27 Locations for this study
Columbus Ohio, 43210, United States
Dallas Texas, 75251, United States
Buenos Aires , C1125, Argentina
Innsbruck , A-602, Austria
Beijing , 10003, China
Copenhagen , DK-21, Denmark
Lyon Cedex , 69373, France
Nantes Cedex 1 , 44093, France
Paris , 75970, France
Villejuif Cedex , 94800, France
Mannheim Baden-Wuerttemberg, 68305, Germany
Berlin , 13353, Germany
Hamburg , 20246, Germany
Heidelberg , 69120, Germany
Budapest , H 112, Hungary
Debrecen , 4032, Hungary
Kashiwa Chiba, 277 8, Japan
Chuo ku Tokyo, 104 0, Japan
Rotterdam , 3075 , Netherlands
Utrecht , 3584C, Netherlands
Barcelona Catalunya, 08035, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Madrid , 28050, Spain
Songkla , 90110, Thailand
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.